Four Research Areas
with the aim to improve the prognosis of subjects diagnosed with CRC
What causes colorectal cancer?
The aim is to identify a possible association between genetics in feces (bacterial, viral,
fungal DNA), in blood and in tumor tissue.
Specific toxins may lead to DNA mutations that may be the early onset of neoplasia leading to malignancy.
Early detection (screening)
- Compliance rates > 90%
- Significant detection of bowel neoplasia (benign as well as malignant)
- Significant detection of extra-colonic malignancy
Screening based on analyses for cancer-associated biomarkers in blood
- Compliance rates
- Early detection of bowel malignancy (= improved overall survival)
- Early detection of benign bowel neoplasia (= reduced incidence of bowel malignancy)
- Frequency in testing which may improve early detection of neoplasia
Our present research projects:
with a focus on identification, validation and implementation of a blood-based biomarker test for screening of large bowel neoplasia.
From early 2014 to ultimo 2016, the project was associated the current public screening offered to all Danish Citizens 50–74 years of age.
Part 2—initiated in full in September 2016:
with the focus to be able to identify subjects who,although tested FIT negative,
may have bowel or extra-colonic neoplasia or alternatively, have a
high risk of developing future neoplasia.
Blood samples and data are collected 3 times from 30,000 subjects
who have been screened FIT negative at 3 consecutive screening-rounds
—i.e. subsequent collections after 2 and 4 years, respectively
Ultimo February 2018 32.665 individuals were included in the project.
Collection round 2 was initiated per March 2018—ultimo June 2019, 13.918 of those included in round 1 were included the second time. The inclusion rate keeping up the expected 75% of those in round 1.
The results from this project will be available by late 2023.
Triage in selection to diagnostic colonoscopy
of subjects with symptoms attributable to colorectal cancer (CRC):
From spring 2018 to ultimo 2020 our 3-step screening-concept
will be validated in use for a more accurate selection of only the neccessary colonoscopies
among subjects referred to diagnostic colonoscopy because of symptoms of CRC.
Due to the success of the CRC-screening in Denmark, the total need of colonoscopies
has far exceeded the overall capacity.
As up to 80% of all colonoscopy show no treatment demanding findings, our TRIAGE-concept
(= (1) a person’s age + (2) a FIT+ – test (=test for occult blood in feces) + (3) a blood-based biomarker test)
are tested in use for, also, the selection of subjects with symptoms of CRC referred to diagnostic colonoscopy.
Early detection of recurrence
In this area the overall research has focus on identification, validation and implementation of a test for cancer-associated biomarkers in blood that may detect recurrence early.
Early detection will lead to improved ability to institute renewed curative treatment—hence, improving the overall prognosis significantly.
Validation of preanalytical issues
Specific minor research studies focusing on issues that may influence the proper interpretation of the results achieved from the major, clinical studies
—i.e such as procedures around blood collection, handling and storage of the tests etc.
A continuous documentation and further qualification of our final results.
Generated cooperative relations with national and international research groups,
including academic institutions and biotech companies,
lead to improved options for the analyses of all the collected tests and data by access to
the collaborators’ specifically invented analysis platforms.
Based on such collaborative approaches, we have achieved results
that may play a significant role in the daily clinical routine and practice.